- Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
May 7, 2026 · globenewswire.com
NEWTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on Thursday, May 14, 2026, at 8:55 a.m.
- ACUMEN PHARMACEUTICALS TO PARTICIPATE IN THE BANK OF AMERICA SECURITIES 2026 HEALTH CARE CONFERENCE
May 7, 2026
NEWTON, MASS., MAY 07, 2026 (GLOBE NEWSWIRE) -- ACUMEN PHARMACEUTICALS, INC. (NASDAQ: ABOS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS THAT TARGET TOXIC SOLUBLE AMYLOID BETA OLIGOMERS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, ANNOUNCED TODAY THAT MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE BANK OF AMERICA SECURITIES 2026 HEALTH CARE CONFERENCE ON THURSDAY, MAY 14, 2026, AT 8:55 A.M.
- Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026
May 5, 2026 · globenewswire.com
NEWTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter financial results on Tuesday, May 12, 2026.
- ACUMEN PHARMACEUTICALS TO REPORT FIRST QUARTER FINANCIAL RESULTS ON MAY 12, 2026
May 5, 2026
NEWTON, MASS., MAY 05, 2026 (GLOBE NEWSWIRE) -- ACUMEN PHARMACEUTICALS, INC. (NASDAQ: ABOS) (“ACUMEN” OR THE “COMPANY”), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS THAT TARGET TOXIC SOLUBLE AMYLOID BETA OLIGOMERS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, TODAY ANNOUNCED THAT THE COMPANY WILL REPORT FIRST QUARTER FINANCIAL RESULTS ON TUESDAY, MAY 12, 2026.
- Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Mar 31, 2026 · zacks.com
The heavy selling pressure might have exhausted for Acumen Pharmaceuticals (ABOS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Mar 30, 2026 · zacks.com
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and ADC Therapeutics SA (ADCT) have performed compared to their sector so far this year.
- Analysts Set Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Target Price at $7.00
Mar 30, 2026 · defenseworld.net
Shares of Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the four analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average
- Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding
Mar 26, 2026
Earnings Call Insights: Acumen Pharmaceuticals (ABOS) Q4 2025
MANAGEMENT VIEW
* Daniel O'Connell, CEO, highlighted 2025 as "a year of execution and expansion at Acumen." He reported demonstrable progress for the lead program, sabirnetug, in the Phase II ALTITUDE-AD trial, describing it as a "well-powered Phase II study that is investigating sabirnetug, our monoclonal antibody with high selectivity for A-beta oligomers." He emphasized that "Sabirnetug's selectivity for toxic oligomers is central to why we believe it could unlock potentially greater clinical efficacy and improved safety relative to amyloid plaque-directed antibodies."
* O'Connell announced expansion of the pipeline through the Enhanced Brain Delivery (EBD) partnership with JCR Pharmaceuticals, stating, "We think of EBD as supercharging our antibodies to significantly increase brain penetration and distribution with potentially lower safety risks and in a convenient subcutaneous dosing format."
* Looking ahead, O'Connell said, "2026 is poised to be a transformative year for Acumen. We expect to read out ALTITUDE-AD late this year, inclusive of key clinical efficacy and safety measures."
* James Doherty, President & Chief Development Officer, discussed preclinical EBD program results, saying, "the candidate profiles achieved exceeded our target product profile for the EBD program and catalyzed the roughly $36 million private placement. As of now, we are targeting a filing of an IND for a clinical candidate in mid-'27."
* Matt Zuga, CFO & Chief Business Officer: "We ended 2025 with $116.9 million in cash and marketable securities on our balance sheet, which is expected to support our current clinical and operational activities into early 2027." He added, "R&D expenses were $104.9 million in 2025... G&A expenses were $18.9 million in 2025, the decrease primarily due to reductions in recruiting expenses, corporate insurance expenses and consulting costs. This led to a loss from operations and a net loss of $121.3 million in 2025."
* Zuga noted, "on March 16, 2026, we closed a private placement in support of our EBD program that grossed $35.75 million before offering expenses, which were minimal."
OUTLOOK
* O'Connell projected, "We expect to read out ALTITUDE-AD late this year, inclusive of key clinical efficacy and safety measures." He indicated that results from this study would inform development strategy and understanding of the impact of clearing A-beta oligomers in Alzheimer's patients.
* Doherty stated, "we are targeting a filing of an IND for a clinical candidate in mid-'27" for the EBD program, with ongoing preclinical development supported by recently raised funds.
* Management reiterated confidence in both the ALTITUDE-AD timeline and the EBD program’s progress toward nomination of a lead clinical candidate.
FINANCIAL RESULTS
* Zuga reported, "We ended 2025 with $116.9 million in cash and marketable securities." R&D expenses were $104.9 million in 2025, reflecting increased manufacturing and materials for the ALTITUDE-AD clinical trial and EBD research. G&A expenses were $18.9 million, resulting in a net loss of $121.3 million for 2025.
* The $35.75 million private placement in March 2026 was raised to support the EBD program and general corporate purposes.
Q&A
* Samantha Schaeffer, Cantor Fitzgerald: Asked about ALTITUDE-AD retention and rollover, and how these metrics compare to other studies. Doherty responded, "we've been very pleased with the overall progress of the ALTITUDE study, and that includes what we're seeing both in terms of retention in the study, which we think are...in line with what's been observed in a lot of the other major Alzheimer's trials that have been conducted recently." Siemers added, "the study has run remarkably smoothly...the retention rate has been good. And again, the rollover rate of people going into the open-label extension has been very satisfying."
* Schaeffer asked about EBD preclinical data and what suggests viability. Doherty replied, "in the primate study, we're seeing 14- to 40-fold improvements in overall brain exposure, which is a substantial change in brain levels."
* Matthew Ryan Tan, Stifel: Asked about presenting additional nonhuman primate (NHP) data and how much EBD can improve efficacy over sabirnetug. Doherty said, "we'll continue to tell the story in upcoming scientific meetings" and explained, "we really think that we're going to improve the distribution of antibodies with the technology."
* Jason Zemansky, BofA Securities: Asked about the brain distribution of oligomers and anemia rates. Doherty explained, "there's pretty good evidence that you've got broad distribution of soluble oligomers across multiple cortical and subcortical regions" and attributed lower anemia rates to the JCR technology.
* Thomas Shrader, BTIG: Asked about robustness of EBD uptake and OLE study metrics. Doherty noted, "we're seeing robust increases in levels of antibodies relative to the label controls." Siemers added, "for these open-label extensions...you measure the same things, but you do it generally less frequently." Siemers also noted, "plaque reduction isn't necessarily needed in our case, but it will be a very interesting part of the readout."
* Mary-Kate, Citi: Asked about EBD trial design and physician feedback. Doherty indicated, "we do think that we can take advantage of the fact that we've got quite a lot of clinical experience now with sabirnetug in designing our study." Siemers discussed safety and ARIA, "most cases of ARIA are asymptomatic...The ones that you really worry about are the rare cases of people who have serious symptoms."
* Dev Prasad, Lucid: Asked about OLE dosing selection and Phase III design. Doherty said, "our base case at the moment is that we think that one additional Phase III study should be sufficient...with quite a similar design to the ALTITUDE study." Siemers explained, "at 35 mg per kg, you actually have good target engagement at both peak and trough."
SENTIMENT ANALYSIS
* Analysts pressed for specifics on retention, EBD differentiation, comparative anemia risk, and Phase III planning, reflecting a neutral to slightly positive tone, as questions were constructive and focused on execution and differentiation.
* Management maintained a confident and optimistic tone throughout both prepared remarks and Q&A, as shown by phrases such as "we are confident in our scientific innovation and strong track record of execution" and "we think we're in a really good spot with multiple really robust candidate molecules."
* Compared to the previous quarter, management's tone has shifted from cautious optimism to greater confidence, especially regarding the EBD program and ALTITUDE-AD progress. Analyst tone remained inquisitive but more focused on concrete milestones and differentiation.
QUARTER-OVER-QUARTER COMPARISON
* The current quarter featured the announcement of a $35.75 million private placement to support EBD program development and a clear target for an IND filing in mid-2027.
* Management shifted from monitoring progress and highlighting board changes in the prior quarter to emphasizing pipeline expansion, preclinical data exceeding expectations, and upcoming pivotal trial readouts in the current quarter.
* The focus of analysts' questions shifted from general development strategy to retention, preclinical efficacy, and specifics of post-Phase II plans.
* Key financials showed a decrease in cash and an increase in R&D expenses compared to the previous quarter, while G&A expenses continued to decline.
* Management confidence strengthened, with more direct references to robust candidate profiles and positive trial metrics.
RISKS AND CONCERNS
* Management acknowledged that the ALTITUDE-AD study is ongoing and blinded, with key efficacy and safety data pending until late 2026.
* Doherty noted, "there's a limited amount that you can know for an ongoing blinded study."
* Analyst concerns centered on patient retention, safety signals, the real-world potential of EBD candidates, anemia risk, and trial design decisions for future phases.
* Management emphasized ongoing data collection, diversification of EBD candidates, and leveraging partnerships to address these risks.
FINAL TAKEAWAY
Acumen Pharmaceuticals emphasized 2026 as a pivotal year with the anticipated ALTITUDE-AD Phase II readout expected to inform future strategy in Alzheimer’s treatment. Management highlighted robust progress on both the lead program and EBD pipeline, supported by new funding and preclinical profiles that surpassed expectations. Financial resources are positioned to sustain operations into early 2027, and the company is committed to advancing differentiated antibody therapies targeting Alzheimer’s disease, with an IND filing for EBD set for mid-2027.
Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/abos/earnings/transcripts]
MORE ON ACUMEN PHARMACEUTICALS
* Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript [https://seekingalpha.com/article/4886162-acumen-pharmaceuticals-inc-abos-q4-2025-earnings-call-transcript]
* Seeking Alpha’s Quant Rating on Acumen Pharmaceuticals [https://seekingalpha.com/symbol/ABOS/ratings/quant-ratings]
* Historical earnings data for Acumen Pharmaceuticals [https://seekingalpha.com/symbol/ABOS/earnings]
* Financial information for Acumen Pharmaceuticals [https://seekingalpha.com/symbol/ABOS/income-statement]
- Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript
Mar 26, 2026 · seekingalpha.com
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript
- Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
Mar 26, 2026 · globenewswire.com
NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the full year ended December 31, 2025 and provided a business update.
